Samy Louafi

2.3k total citations
16 papers, 801 citations indexed

About

Samy Louafi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Samy Louafi has authored 16 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Samy Louafi's work include Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Samy Louafi is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Samy Louafi collaborates with scholars based in France, Austria and Canada. Samy Louafi's co-authors include Julien Taı̈eb, David Klatzmann, François M. Lemoine, Touraj Mansourbakht, A Bardier, Frédéric Charlotte, Michèlle Rosenzwajg, Fabrice Mènégaux, J.C. Vaillant and Valérie Boige and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer.

In The Last Decade

Samy Louafi

16 papers receiving 793 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samy Louafi France 9 374 221 217 146 135 16 801
CK Lee South Korea 16 160 0.4× 238 1.1× 186 0.9× 102 0.7× 75 0.6× 40 939
Ulrik Lindforss Sweden 16 296 0.8× 279 1.3× 250 1.2× 72 0.5× 225 1.7× 27 736
Thomas DeLeon United States 10 244 0.7× 237 1.1× 52 0.2× 90 0.6× 45 0.3× 19 526
Peter Moosmann Switzerland 15 264 0.7× 138 0.6× 77 0.4× 77 0.5× 63 0.5× 23 938
Terasu Honma Japan 15 95 0.3× 280 1.3× 105 0.5× 224 1.5× 60 0.4× 75 652
Hülya Çetınkaya Türkiye 17 139 0.4× 162 0.7× 115 0.5× 472 3.2× 211 1.6× 48 989
Akitoshi Kinoshita Japan 19 516 1.4× 96 0.4× 119 0.5× 207 1.4× 79 0.6× 93 1.2k
Sowmya Narayanan United States 13 235 0.6× 194 0.9× 233 1.1× 171 1.2× 16 0.1× 20 668
Xiaoyan Liao United States 16 254 0.7× 311 1.4× 50 0.2× 152 1.0× 74 0.5× 79 821
Hueseyin Bektas Germany 11 162 0.4× 326 1.5× 113 0.5× 111 0.8× 37 0.3× 21 609

Countries citing papers authored by Samy Louafi

Since Specialization
Citations

This map shows the geographic impact of Samy Louafi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samy Louafi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samy Louafi more than expected).

Fields of papers citing papers by Samy Louafi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samy Louafi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samy Louafi. The network helps show where Samy Louafi may publish in the future.

Co-authorship network of co-authors of Samy Louafi

This figure shows the co-authorship network connecting the top 25 collaborators of Samy Louafi. A scholar is included among the top collaborators of Samy Louafi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samy Louafi. Samy Louafi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Meurisse, Aurélia, Pascal Artru, Thierry Lecomte, et al.. (2024). 517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study. Annals of Oncology. 35. S438–S438. 1 indexed citations
2.
Phelip, Jean–Marc, Jérôme Desrame, Julien Edeline, et al.. (2021). Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. Journal of Clinical Oncology. 40(3). 262–271. 79 indexed citations
3.
Phelip, Jean–Marc, Jérôme Desrame, Julien Edeline, et al.. (2020). 52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. Annals of Oncology. 31. S260–S261. 11 indexed citations
4.
Kourié, Hampig Raphaël, Édouard Auclin, António Sá Cunha, et al.. (2019). Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Clinics and Research in Hepatology and Gastroenterology. 43(6). 663–668. 10 indexed citations
5.
Randrian, Violaine, Antoine Adenis, Jérôme Desrame, et al.. (2019). Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and Liver Disease. 52(3). 347–350. 3 indexed citations
6.
Zaanan, Aziz, Emmanuelle Samalin, Christophe Louvet, et al.. (2017). PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma. Annals of Oncology. 28. v265–v265. 4 indexed citations
7.
Bachet, Jean‐Baptiste, Olivier Bouché, Julien Taı̈eb, et al.. (2017). RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.. Journal of Clinical Oncology. 35(15_suppl). 11509–11509. 8 indexed citations
8.
Zaanan, Aziz, Émilie Soularue, Samy Louafi, et al.. (2017). Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. Targeted Oncology. 13(1). 107–112. 5 indexed citations
9.
10.
Barret, Maximilien, David Malka, Thomas Aparicio, et al.. (2011). Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study. Oncology. 81(5-6). 395–402. 81 indexed citations
11.
Barret, Maximilien, Thomas Aparicio, Franck Bonnetain, et al.. (2011). Does nutritional status affect treatment tolerability and efficacy in metastatic colorectal cancer (mCRC) patients? Results of a prospective multicenter study.. Journal of Clinical Oncology. 29(15_suppl). e14018–e14018. 2 indexed citations
12.
Guillot‐Delost, Maude, Sabine Le Gouvello, Mariana Mesel‐Lemoine, et al.. (2011). Human CD90 Identifies Th17/Tc17 T Cell Subsets That Are Depleted in HIV-Infected Patients. The Journal of Immunology. 188(3). 981–991. 38 indexed citations
13.
Louafi, Samy, A Bardier, Frédéric Charlotte, et al.. (2008). Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue. Gut. 58(4). 520–529. 208 indexed citations
14.
Louafi, Samy, Valérie Boige, Michel Ducreux, et al.. (2007). Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Cancer. 109(7). 1384–1390. 145 indexed citations
15.
Nerich, Virginie, Élisabeth Monnet, Samy Louafi, et al.. (2006). Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data. Inflammatory Bowel Diseases. 12(3). 218–226. 127 indexed citations
16.
Louafi, Samy, Touraj Mansourbakht, Luminita Bonyhay, & Julien Taı̈eb. (2006). [Oxaliplatin in gastro-intestinal tract cancer except colorectal cancer].. PubMed. 93 Suppl 1. S23–33. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by CK Lee Breakdown of academic impact, for papers by Ulrik Lindforss Breakdown of academic impact, for papers by Thomas DeLeon Breakdown of academic impact, for papers by Peter Moosmann Breakdown of academic impact, for papers by Terasu Honma Breakdown of academic impact, for papers by Hülya Çetınkaya Breakdown of academic impact, for papers by Akitoshi Kinoshita Breakdown of academic impact, for papers by Sowmya Narayanan Breakdown of academic impact, for papers by Xiaoyan Liao Breakdown of academic impact, for papers by Hueseyin Bektas
Rankless by CCL
2026